ONCOGENIC E6E7 mRNA Test
Cost: AED 700.0
Introduction
The ONCOGENIC E6E7 mRNA test is a diagnostic test used to detect the presence of high-risk human papillomavirus (HPV) strains in cervical cells. This blog post will provide detailed information about the test, including its components, price, sample condition, report delivery, method, test type, and the doctors involved.
Test Components and Price
The ONCOGENIC E6E7 mRNA test is priced at AED 700.0. It involves the submission of cervical swab/cells in a special container with medium available from LPL. The sample should be shipped refrigerated and should not be frozen. After collection, the specimen should be stored at 2-8°C immediately to maintain sample quality.
Report Delivery
The sample for the ONCOGENIC E6E7 mRNA test is collected on Tuesdays, Thursdays, and Saturdays by 9 am, and the report is delivered on Wednesdays, Fridays, and Mondays.
Method and Test Type
The ONCOGENIC E6E7 mRNA test is performed using flow cytometry, a method that allows for the analysis of cells based on their physical and chemical characteristics. It is a test specifically designed for cancer detection.
Doctors Involved
The ONCOGENIC E6E7 mRNA test is typically ordered by gynecologists and oncologists, who specialize in the diagnosis and treatment of cervical cancer.
Pre Test Information
It is important to avoid exposing the specimen to high temperatures, as it can adversely affect the quality of the sample.
Test Details
The oncogenic E6/E7 mRNA test is used to detect the presence of high-risk HPV strains in cervical cells. HPV is a common sexually transmitted infection that can lead to the development of cervical cancer. The E6 and E7 genes of high-risk HPV strains are known to play a role in the development of cervical cancer. The oncogenic E6/E7 mRNA test specifically detects the presence of the messenger RNA (mRNA) of these genes in cervical cells. mRNA is a type of genetic material that carries instructions for the production of proteins within cells.
By detecting the presence of oncogenic E6/E7 mRNA, the test can identify women who are at a higher risk of developing cervical cancer. This information can be used to guide further testing and management decisions, such as determining the need for colposcopy or monitoring the progression of HPV infection.
The oncogenic E6/E7 mRNA test is typically performed in conjunction with a Pap smear or HPV DNA test as part of cervical cancer screening. It is a more specific test compared to HPV DNA testing alone, as it directly detects the expression of the oncogenic genes involved in cervical cancer development.
It is important to note that the oncogenic E6/E7 mRNA test is not a standalone diagnostic test for cervical cancer. It is used as an adjunct test to provide additional information about the presence of high-risk HPV strains and the potential risk for cervical cancer development. A positive result on the oncogenic E6/E7 mRNA test may warrant further evaluation, such as a colposcopy or biopsy, to confirm the presence of precancerous or cancerous cervical cells.
| Test Name | ONCOGENIC E6E7 mRNA Test |
|---|---|
| Components | |
| Price | 700.0 AED |
| Sample Condition | Submit Cervical swab \/ cells in special container with medium available from LPL. Ship refrigerated. DO NOT FREEZE. Store specimen at 2-8?\u00f8C immediately after collection. Exposure of the specimen to high temperatures has adverse effects on sample quality. |
| Report Delivery | SampleTue /Thu / Sat by 9 am; ReportWed / Fri / Mon |
| Method | Flow Cytometry |
| Test type | Cancer |
| Doctor | Gynecologist, Oncologist |
| Test Department: | FLOW CYTOMETRY |
| Pre Test Information | Exposure of the specimen to high temperatures has adverse effects on sample quality. |
| Test Details | The oncogenic E6/E7 mRNA test is a diagnostic test used to detect the presence of high-risk human papillomavirus (HPV) strains in cervical cells. HPV is a common sexually transmitted infection that can lead to the development of cervical cancer. The E6 and E7 genes of high-risk HPV strains are known to play a role in the development of cervical cancer. The oncogenic E6/E7 mRNA test specifically detects the presence of the messenger RNA (mRNA) of these genes in cervical cells. mRNA is a type of genetic material that carries instructions for the production of proteins within cells. By detecting the presence of oncogenic E6/E7 mRNA, the test can identify women who are at a higher risk of developing cervical cancer. This information can be used to guide further testing and management decisions, such as determining the need for colposcopy or monitoring the progression of HPV infection. The oncogenic E6/E7 mRNA test is typically performed in conjunction with a Pap smear or HPV DNA test as part of cervical cancer screening. It is a more specific test compared to HPV DNA testing alone, as it directly detects the expression of the oncogenic genes involved in cervical cancer development. It is important to note that the oncogenic E6/E7 mRNA test is not a standalone diagnostic test for cervical cancer. It is used as an adjunct test to provide additional information about the presence of high-risk HPV strains and the potential risk for cervical cancer development. A positive result on the oncogenic E6/E7 mRNA test may warrant further evaluation, such as a colposcopy or biopsy, to confirm the presence of precancerous or cancerous cervical cells. |
